Case report: Plasma cell leukemia secondary to multiple myeloma successfully treated with anti-BCMA CAR-T cell therapy

Case report: Plasma cell leukemia secondary to multiple myeloma successfully treated with anti-BCMA CAR-T cell therapy

Chimeric antigen receptor (CAR)-T cell therapy provides an effective salvage treatment for relapsed/refractory multiple myeloma (RRMM) patients. End-stage RRMM with plasma cell leukemia (PCL) transformation is highly aggressive and resistant to conventional therapy. There is an urgent need for new t...

Full description

Bibliographic Details
Main Authors:	Jingjing Deng, Yuehui Lin, Defeng Zhao, Chunrong Tong, Alex H. Chang, Wenming Chen, Wen Gao
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-09-01
Series:	Frontiers in Oncology
Subjects:	plasma cell leukemia relapsed/refractory multiple myeloma chimeric antigen receptor T cell therapy secondary plasma cell leukemia treatment
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2022.901266/full

Similar Items

A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia
by: Chunrui Li, et al.
Published: (2021-03-01)

Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease
by: Haobin Deng, et al.
Published: (2021-08-01)

Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
by: Lihong An, et al.
Published: (2022-04-01)

Prominent efficacy and good safety of sequential CD19 and CD22 CAR-T therapy in relapsed/refractory adult B-cell acute lymphoblastic leukemia
by: Tingting Yang, et al.
Published: (2025-01-01)

Therapeutic effect of CAR-γδT cells targeting at BCMA in multiple myeloma
by: LI Yinghui, XU Yi, ZHANG Jianmin, CHEN Hui, HE Wei
Published: (2024-06-01)

CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia
by: Xuanqi Cao, et al.
Published: (2022-09-01)

A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed/refractory multiple myeloma patients treated with CAR-T cells
by: Yang Liu, et al.
Published: (2023-04-01)

Impact of glucocorticoids on short-term and long-term outcomes in patients with relapsed/refractory multiple myeloma treated with CAR-T therapy
by: Xue Wang, et al.
Published: (2022-08-01)

Haploidentical CD7 CAR T-cells induced remission in a patient with TP53 mutated relapsed and refractory early T-cell precursor lymphoblastic leukemia/lymphoma
by: Hai-ping Dai, et al.
Published: (2022-02-01)

Decitabine in combination with fludarabine and cyclophosphamide as a lymphodepletion regimen followed by CD19/CD22 bispecific targeted CAR T-cell therapy significantly improves survival in relapsed/refractory B-ALL patients
by: Yunju Ma, et al.
Published: (2023-04-01)

Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma
by: Kevin Miller, et al.
Published: (2024-05-01)

Rare case of plasma cell myeloma with megakaryoblastic morphology mimicking acute leukemia
by: Keyu Liu, et al.
Published: (2020-01-01)

Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma
by: Jinhuan Xu, et al.
Published: (2018-10-01)

Preclinical delayed toxicity studies of BCMA CAR T-cell injection in B-NDG mice with multiple myeloma
by: Jianmin Guo, et al.
Published: (2024-11-01)

A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia
by: Jianyu Weng, et al.
Published: (2018-02-01)

Targeting BCMA in multiple myeloma: designs, challenges, and future directions
by: Yi Hu, et al.
Published: (2025-02-01)

Bilateral orbital plasmacytomas as first sign of extramedullary progression post CAR-T therapy: case report and literature review
by: Javier Nogués-Castell, et al.
Published: (2023-08-01)

CAR NK92 Cells Targeting BCMA Can Effectively Kill Multiple Myeloma Cells Both In Vitro and In Vivo
by: Eunhee Park, et al.
Published: (2024-01-01)

CD19 chimeric antigen receptor-T cells as bridging therapy to allogeneic hematopoietic cell transplantation improves outcome in patients with refractory/relapsed B-cell acute lymphoblastic leukemia
by: Jie Liu, et al.
Published: (2024-07-01)

Plasma cell myeloma following a prior diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma
by: Melissa N. Loyzer, et al.
Published: (2022-12-01)

Outcomes with chimeric antigen receptor t-cell therapy in relapsed or refractory acute myeloid leukemia: a systematic review and meta-analysis
by: Moazzam Shahzad, et al.
Published: (2023-04-01)

Successful treatment with bortezomib-containing regimen of primary plasma cell leukemia: a case report
by: Mohammad Bader Obeidat, et al.
Published: (2020-05-01)

Rapidly Progressing Plasma Cell Leukemia with Underlying Plasmablastic Morphology: A Rare Case Report of a 25-Year Old Male
by: Smitha Saldanha, et al.
Published: (2022-07-01)

A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
by: Heng Mei, et al.
Published: (2021-10-01)

CAR-T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA
by: Ugo Testa, et al.
Published: (2024-04-01)

Hairy-plasma cell leukemia
by: Nahlah Alghasham, et al.
Published: (2015-01-01)

Ciltacabtagene Autoleucel for the Treatment of Relapsed/Refractory Multiple Myeloma: Efficacy, Safety, and Place in Therapy
by: Goel U, et al.
Published: (2025-02-01)

Primary plasma cell leukemia: A report of two cases of a rare and aggressive variant of plasma cell myeloma with the review of literature
by: Prithal Gangadhar, et al.
Published: (2016-01-01)

Component Costs of CAR-T Therapy in Addition to Treatment Acquisition Costs in Patients with Multiple Myeloma
by: Sundar Jagannath, et al.
Published: (2023-04-01)

Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma
by: Hujun Li, et al.
Published: (2022-10-01)

A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
by: Wan-Hong Zhao, et al.
Published: (2018-12-01)

Biomarkers for Chimeric Antigen Receptor T Cell Therapy in Acute Lymphoblastic Leukemia: Prospects for Personalized Management and Prognostic Prediction
by: Ruimin Hong, et al.
Published: (2021-02-01)

Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy
by: Wei Chen, et al.
Published: (2021-10-01)

C3aR costimulation enhances the antitumor efficacy of CAR-T cell therapy through Th17 expansion and memory T cell induction
by: Peilong Lai, et al.
Published: (2022-05-01)

Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma
by: Lina Zhang, et al.
Published: (2021-01-01)

Editorial: Efficacy and safety of CAR-T cell therapy in hematologic malignancies
by: Marcos de Lima, et al.
Published: (2024-08-01)

Leukemia with Plasma Cells — Case Report
by: Benedek István, et al.
Published: (2017-09-01)

Immunoglobulin D multiple myeloma, plasma cell leukemia and chronic myelogenous leukemia in a single patient treated simultaneously with lenalidomide, bortezomib, dexamethasone and imatinib
by: Naveed Ali, et al.
Published: (2016-03-01)

Clinical features and outcomes of plasma cell leukemia: a single-institution experience in the era of novel agents
by: Giampaolo Talamo, et al.
Published: (2012-08-01)

The influence of CRS and ICANS on the efficacy of anti-CD19 CAR-T treatment for B-cell acute lymphoblastic leukemia
by: Yuhan Ma, et al.
Published: (2024-09-01)